Pomerantz LLP Investigates Securities Fraud Claims Against ADMA Biologics
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy ADMA?
Source: Globenewswire
- Securities Fraud Investigation: Pomerantz LLP is investigating whether ADMA Biologics has engaged in securities fraud or other unlawful business practices, aiming to protect investor rights and potentially initiate a class action lawsuit.
- Short Report Allegations: On March 24, 2026, Culper Research published a report alleging that ADMA's growth figures are fictitious, primarily driven by a channel stuffing scheme, estimating a 3% revenue decline in 2025 instead of the reported 20% growth.
- Stock Price Plunge: Following the release of the short report, ADMA's stock price fell by $2.26, or 16.63%, closing at $11.33 per share on March 24, 2026, reflecting market concerns over the company's financial transparency.
- Rating Downgrade Impact: Cantor Fitzgerald downgraded ADMA's rating on March 26, 2026, citing disappointment with the company's response to the short report, which lacked specific feedback, resulting in a further stock price drop of $1.34, or 13.91%, to close at $8.29 per share, exacerbating investor anxiety.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ADMA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ADMA
About ADMA
ADMA Biologics, Inc. is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The Company manufactures and markets three United States Food and Drug Administration (FDA)-approved plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases: ASCENIV (immune globulin intravenous, human-slra 10% liquid) for the treatment of primary humoral immunodeficiency (PI); BIVIGAM (immune globulin intravenous, human) for the treatment of PI; and NABI-HB (hepatitis B immune globulin, human) to provide enhanced immunity against the hepatitis B virus. Through its ADMA BioCenters subsidiary, the Company also operates as an FDA-approved source plasma collector in the United States, which provides its blood plasma for the manufacture of its products.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Pomerantz LLP Investigates Securities Fraud Claims Against ADMA Biologics
- Securities Fraud Investigation: Pomerantz LLP is investigating whether ADMA Biologics has engaged in securities fraud or other unlawful business practices, aiming to protect investor rights and potentially initiate a class action lawsuit.
- Short Report Allegations: On March 24, 2026, Culper Research published a report alleging that ADMA's growth figures are fictitious, primarily driven by a channel stuffing scheme, estimating a 3% revenue decline in 2025 instead of the reported 20% growth.
- Stock Price Plunge: Following the release of the short report, ADMA's stock price fell by $2.26, or 16.63%, closing at $11.33 per share on March 24, 2026, reflecting market concerns over the company's financial transparency.
- Rating Downgrade Impact: Cantor Fitzgerald downgraded ADMA's rating on March 26, 2026, citing disappointment with the company's response to the short report, which lacked specific feedback, resulting in a further stock price drop of $1.34, or 13.91%, to close at $8.29 per share, exacerbating investor anxiety.
See More
Rosen Law Firm Investigates ADMA Biologics for Misleading Information
- Securities Claims Investigation: Rosen Law Firm is investigating ADMA Biologics for potentially issuing materially misleading business information, which may expose shareholders to significant securities claims.
- Stock Price Plunge: On March 24, 2026, ADMA Biologics' stock fell by 16.6% following allegations from short seller Culper Research that the company engaged in channel stuffing to inflate revenue growth, directly impacting investor confidence.
- Class Action Preparation: The firm is preparing a class action to seek compensation for investor losses, with a contingency fee arrangement that allows investors to join without upfront costs, thereby reducing their legal risk.
- Law Firm's Reputation: Rosen Law Firm is recognized for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, demonstrating its expertise and resource advantages in handling such cases.
See More
ADMA Biologics Under Investigation for Securities Violations
- Investigation Announcement: Bleichmar Fonti & Auld LLP has initiated an investigation into ADMA Biologics for potential violations of federal securities laws, urging investors to seek additional information regarding their legal options.
- Revenue Growth Scrutiny: Allegations suggest that ADMA's reported 20% revenue growth in 2025 may have been artificially inflated through a channel stuffing scheme, raising concerns about the company's financial integrity and actual market demand.
- Stock Price Plunge: Following a report from Culper Research that exposed these practices, ADMA's stock price plummeted by 29% over two trading days, from $13.59 to $9.63 per share, indicating significant market distrust in the company's financial disclosures.
- Legal Implications: Investors may have legal recourse, as BFA offers representation on a contingency basis, emphasizing the firm's commitment to safeguarding shareholder interests amidst these serious allegations.
See More
Rosen Law Firm Investigates ADMA Biologics for Potential Securities Claims
- Securities Claims Investigation: Rosen Law Firm has announced an investigation into ADMA Biologics for potentially issuing materially misleading business information, which, if confirmed, could severely impact the company's reputation and stock price.
- Stock Price Plunge: On March 24, 2026, ADMA Biologics shares fell by 16.6% after short seller Culper Research alleged the company engaged in channel stuffing to inflate revenue, indicating a significant loss of market confidence in the company's financial transparency.
- Class Action Preparation: The Rosen Law Firm is preparing a class action to seek recovery for investor losses, allowing affected shareholders to participate without any out-of-pocket fees, which could provide substantial economic compensation for those impacted.
- Law Firm's Strength: Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, demonstrating its strong track record and success in the field, thereby enhancing investor trust in their representation.
See More
ADMA Biologics Faces Securities Investigation Amid Allegations
- Investigation Launched: Rosen Law Firm has announced an investigation into ADMA Biologics for potential securities claims due to allegations of issuing materially misleading business information, which may entitle shareholders to compensation.
- Stock Price Impact: On March 24, 2026, ADMA Biologics' stock plummeted by 16.6% after short seller Culper Research alleged the company engaged in channel stuffing to inflate revenue growth, significantly undermining investor confidence.
- Class Action Preparation: The Rosen Law Firm is preparing a class action to recover investor losses, allowing participation without any upfront fees, thereby lowering the financial barrier for affected investors.
- Firm's Reputation: Rosen Law Firm is recognized for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, demonstrating its strength and experience in handling similar cases.
See More
ADMA Biologics Under Investigation for Potential Securities Fraud
- Investigation Announcement: Bleichmar Fonti & Auld LLP has initiated an investigation into ADMA Biologics for potential violations of federal securities laws, as allegations arise that the reported 20% revenue growth in 2025 may have been artificially inflated through channel stuffing, indicating serious concerns about the company's financial transparency.
- Revenue Growth Scrutiny: A report by Culper Research claims that ADMA induced a distributor to stockpile ASCENIV by offering rebates and extended payment terms, which allegedly allowed the company to book revenue that was not genuinely realized; without this scheme, the company would have faced a 3% revenue decline in 2025, severely impacting investor confidence.
- Stock Price Plunge: Following the investigation and the report's findings, ADMA Biologics' stock price plummeted by 29% over two trading days, falling from $13.59 per share on March 23 to $9.63 per share on March 25, reflecting market concerns regarding the company's financial health and future prospects.
- Legal Options for Investors: Investors are encouraged to submit their information for legal assistance, with BFA offering representation on a contingency fee basis, indicating strong support for affected shareholders and potentially leading to increased legal actions seeking compensation.
See More
Pomerantz LLP Investigates Securities Fraud Claims Against ADMA Biologics
- Securities Fraud Investigation: Pomerantz LLP is investigating whether ADMA Biologics has engaged in securities fraud or other unlawful business practices, aiming to protect investor rights and potentially initiate a class action lawsuit.
- Short Report Allegations: On March 24, 2026, Culper Research published a report alleging that ADMA's growth figures are fictitious, primarily driven by a channel stuffing scheme, estimating a 3% revenue decline in 2025 instead of the reported 20% growth.
- Stock Price Plunge: Following the release of the short report, ADMA's stock price fell by $2.26, or 16.63%, closing at $11.33 per share on March 24, 2026, reflecting market concerns over the company's financial transparency.
- Rating Downgrade Impact: Cantor Fitzgerald downgraded ADMA's rating on March 26, 2026, citing disappointment with the company's response to the short report, which lacked specific feedback, resulting in a further stock price drop of $1.34, or 13.91%, to close at $8.29 per share, exacerbating investor anxiety.
See More
Rosen Law Firm Investigates ADMA Biologics for Misleading Information
- Securities Claims Investigation: Rosen Law Firm is investigating ADMA Biologics for potentially issuing materially misleading business information, which may expose shareholders to significant securities claims.
- Stock Price Plunge: On March 24, 2026, ADMA Biologics' stock fell by 16.6% following allegations from short seller Culper Research that the company engaged in channel stuffing to inflate revenue growth, directly impacting investor confidence.
- Class Action Preparation: The firm is preparing a class action to seek compensation for investor losses, with a contingency fee arrangement that allows investors to join without upfront costs, thereby reducing their legal risk.
- Law Firm's Reputation: Rosen Law Firm is recognized for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, demonstrating its expertise and resource advantages in handling such cases.
See More
ADMA Biologics Under Investigation for Securities Violations
- Investigation Announcement: Bleichmar Fonti & Auld LLP has initiated an investigation into ADMA Biologics for potential violations of federal securities laws, urging investors to seek additional information regarding their legal options.
- Revenue Growth Scrutiny: Allegations suggest that ADMA's reported 20% revenue growth in 2025 may have been artificially inflated through a channel stuffing scheme, raising concerns about the company's financial integrity and actual market demand.
- Stock Price Plunge: Following a report from Culper Research that exposed these practices, ADMA's stock price plummeted by 29% over two trading days, from $13.59 to $9.63 per share, indicating significant market distrust in the company's financial disclosures.
- Legal Implications: Investors may have legal recourse, as BFA offers representation on a contingency basis, emphasizing the firm's commitment to safeguarding shareholder interests amidst these serious allegations.
See More
Rosen Law Firm Investigates ADMA Biologics for Potential Securities Claims
- Securities Claims Investigation: Rosen Law Firm has announced an investigation into ADMA Biologics for potentially issuing materially misleading business information, which, if confirmed, could severely impact the company's reputation and stock price.
- Stock Price Plunge: On March 24, 2026, ADMA Biologics shares fell by 16.6% after short seller Culper Research alleged the company engaged in channel stuffing to inflate revenue, indicating a significant loss of market confidence in the company's financial transparency.
- Class Action Preparation: The Rosen Law Firm is preparing a class action to seek recovery for investor losses, allowing affected shareholders to participate without any out-of-pocket fees, which could provide substantial economic compensation for those impacted.
- Law Firm's Strength: Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, demonstrating its strong track record and success in the field, thereby enhancing investor trust in their representation.
See More
ADMA Biologics Faces Securities Investigation Amid Allegations
- Investigation Launched: Rosen Law Firm has announced an investigation into ADMA Biologics for potential securities claims due to allegations of issuing materially misleading business information, which may entitle shareholders to compensation.
- Stock Price Impact: On March 24, 2026, ADMA Biologics' stock plummeted by 16.6% after short seller Culper Research alleged the company engaged in channel stuffing to inflate revenue growth, significantly undermining investor confidence.
- Class Action Preparation: The Rosen Law Firm is preparing a class action to recover investor losses, allowing participation without any upfront fees, thereby lowering the financial barrier for affected investors.
- Firm's Reputation: Rosen Law Firm is recognized for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, demonstrating its strength and experience in handling similar cases.
See More
ADMA Biologics Under Investigation for Potential Securities Fraud
- Investigation Announcement: Bleichmar Fonti & Auld LLP has initiated an investigation into ADMA Biologics for potential violations of federal securities laws, as allegations arise that the reported 20% revenue growth in 2025 may have been artificially inflated through channel stuffing, indicating serious concerns about the company's financial transparency.
- Revenue Growth Scrutiny: A report by Culper Research claims that ADMA induced a distributor to stockpile ASCENIV by offering rebates and extended payment terms, which allegedly allowed the company to book revenue that was not genuinely realized; without this scheme, the company would have faced a 3% revenue decline in 2025, severely impacting investor confidence.
- Stock Price Plunge: Following the investigation and the report's findings, ADMA Biologics' stock price plummeted by 29% over two trading days, falling from $13.59 per share on March 23 to $9.63 per share on March 25, reflecting market concerns regarding the company's financial health and future prospects.
- Legal Options for Investors: Investors are encouraged to submit their information for legal assistance, with BFA offering representation on a contingency fee basis, indicating strong support for affected shareholders and potentially leading to increased legal actions seeking compensation.
See More
